Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 18Recruiting 15Terminated 3Not yet recruiting 2Suspended 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

RAS/BRAF Wild-type Advanced Colorectal Cancer Patients 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 126Cisplatin 125Drug Therapy 103Bevacizumab 98Oxaliplatin 97Capecitabine 97Radiotherapy 94Gemcitabine 87Paclitaxel 85tislelizumab 84Cyclophosphamide 82pembrolizumab 77Specimen Handling 77toripalimab 69Injections 63Fluorouracil 62Magnetic Resonance Spectroscopy 61sintilimab 57anlotinib 53130-nm albumin-bound paclitaxel 51Surgical Procedures, Operative 50Docetaxel 49fludarabine 46Pemetrexed 45venetoclax 42Standard of Care 42Leucovorin 42Irinotecan 41lenvatinib 40Biopsy 39

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × amivantamab × Clear all
NCT07586202 2026-05-14

AmiNA

Janssen Research & Development, LLC

Phase 2 Not yet recruiting
68 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06855849 2025-03-04

An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.

Yonsei University

Phase 2 Not yet recruiting
85 enrolled
Gastrointestinal

RAS/BRAF Wild-type Advanced Colorectal Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡